Risk factors for bleeding during treatment with anti-thrombotics

Thesis

Cover

Titlepage

Contents

Chapter 1 Introduction and outline of the thesis

Chapter 2 For the initial treatment of venous thromboembolism: Are all low-molecular-weight heparin compounds the same?

Chapter 3 Vitamin K antagonists or low-molecular-weight heparin for the long-term treatment of venous thromboembolism.

Chapter 4 FACTors in Oral Anticoagulant Safety: study-design and first results

Chapter 5 Haemostatic profiles and bleeding during treatment with vitamin K antagonists

Chapter 6 Cytochrome P-450 2C9 polymorphisms impair acenocoumarol and phenprocoumon metabolism without increasing the bleeding risk

Chapter 7 Functional polymorphisms in GPIa, GPIIIa, PAI-1, TAFI, and FXIIIA genes do not determine bleeding risk during vitamin K antagonist treatment

Chapter 8 Treatment with vitamin K antagonists: frequency of indications and appropriateness of continuation.

Chapter 9 Indication for vitamin K antagonist treatment does not influence bleeding risk

Chapter 10 Fatal outcome of intracranial hemorrhage in patients treated with antiplatelet therapy or oral anticoagulant treatment

Chapter 11 The prevalence of hemosiderin depositions in patients with non-traumatic spontaneous deep intracerebral hemorrhages

Summary

Samenvatting

Appendix 1

Curriculum Vitae

Dankwoord

References

Stellingen behorend bij het proefschrift

Cover